About Eigen Bio

Eigen Bio is building the intelligence substrate that medicine has always needed: a way to rigorously decode biological response in humans.

The most consequential decisions in drug development and patient care depend on understanding how biology regulates itself and how that regulation changes under disease and treatment. Today, most approaches can describe what biology looks like at a given moment, but struggle to predict what it will do next — how it will respond to an intervention, where resistance will emerge, or which patients will benefit. That gap between observation and mechanism is where the most expensive failures happen, and where the most important opportunities are missed.

Eigen Bio exists to close that gap. Our platform combines a regulatory foundation model with a mechanistic knowledge graph to model the regulatory relationships that govern biology — the connections through which genes, transcripts, proteins, and pathways control one another — and how those connections shift under intervention. The result is interpretable, mechanistically grounded biology: response programs, resistance patterns, biomarker hypotheses, patient stratification, and target opportunities that support higher-conviction decisions across drug development, diagnostics, and patient care.

The platform is pan-indication by design, supporting programs across oncology, liver disease, metabolic disease, autoimmune disease, and other complex conditions. It is built to work with partners' proprietary data within their own secured environments, so that the intelligence generated stays where strategic control belongs.

Building this kind of platform requires a team that is fluent across boundaries and relentlessly open and curious — scientists who think computationally, engineers who understand biological measurement, and translational leaders who hold the work to the standard patients deserve. Eigen Bio operates across San Francisco, Seoul, and New York with the rigor of a clinical laboratory and the urgency of a company that knows the stakes are real.